YiChang HEC ChangJiang Pharmaceutical Co., Ltd. provided earnings guidance for the year ended December 31, 2017. For the year, the company expects that it will record a no less than 70% increase in its profit attributable to equity shareholders of the company as compared to that for the year ended December 31, 2016. The expected increase in profit attributable to equity shareholders of the company is primarily attributed to: the significant increase in the sales volume of the company's key product Kewei and the continuous optimisation of the company's academic promotion activities.